Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease

By Dean Bonnie B.   Dylan Michelle   Gano Anacleto   Knight Kevin   Ofman Joshua J.   Levine Barton S.  

Current Medical Research and Opinion, Vol. 21, Iss. 7, 2005-07 ,pp. : 981-988

Informa Healthcare

Access to resources Recommend Favorite

Frequency of Administration of Erythropoiesis‐Stimulating Agents for the Anaemia of End‐Stage Kidney Disease in Dialysis

By  

NEPHROLOGY, Vol. 20, Iss. 9, 2015-09 ,pp. : 663-665

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment with high dose of erythropoiesis‐stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 10, 2015-10 ,pp. : 1068-1075

John Wiley & Sons Inc

Access to resources Recommend Favorite